Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"
20-12-15 AMAG Pharmaceuticals : Files Submission in Response to the Food and Drug Administration's Notice of Opportunity for a Hearing and Proposal to Withdraw Approval of Makena AQ
20-12-14 AMAG Pharmaceuticals : Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) PU
20-11-17 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
20-11-17 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
20-11-16 AMAG Pharmaceuticals : Covis Group Completes Acquisition of AMAG Pharmaceuticals AQ
Manager TitleAgeSince
Director of Finance/CFO - -
President 52 -
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member 52 -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
20-11-15Issuer sale

Director

131,728 0.3818%
20-11-15Issuer sale

Chief Financial Officer

41,038 0.1189%
20-11-15Issuer sale

Director

117,837 0.3415%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+0.29% - - 477M
-1.21%-3.04%+44.03%+143.07% 980B
-2.48%-5.18%+52.47%+39.15% 550B
-2.14%-4.94%+16.83%+57.08% 382B
+0.25%-3.09%+23.33%+16.04% 316B
+0.61%-1.69%+27.35%+13.73% 272B
+0.22%-3.10%+24.67%+30.49% 268B
+4.59%+1.98%-38.43%-46.26% 199B
-1.19%-4.95%+16.68%+47.69% 182B
-1.35%-1.46%+14.06%+59.26% 154B
Average -0.26%-3.02%+20.11%+40.03% 366.93B
Weighted average by Cap. -0.78%-3.68%+29.49%+63.31%
Logo AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Employees
-
  1. Stock Market
  2. Stocks
  3. AMAG Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!